IGHE and allergic asthma: As shown in Figure 1C, since 2000, the analysis of burstiness revealed that the top three references with the strongest citation bursts are “Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma”, “The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics”, and “Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy” (GINA 2002 step 4 treatment): INNOVATE.